India Glycols Ltd
India Glycols Ltd
Consumer GoodsKey Fundamentals
MicrocapBreweries & DistilleriesConsumer GoodsInsights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view India Glycols Ltd insights
43 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Weaknesses
1- Company has a low return on equity of 10.4% over last 3 years.
Growth Rate
AI Analysis — Bull vs Bear
India Glycols Ltd is a diversified green petrochemical and potable spirits company trading at a market cap of ₹7,678 Cr with a P/E of 25.9x. The company has delivered 17% compounded sales growth over 3 years and 39% compounded profit growth over the same period, though its return on equity remains modest at around 10-11%. Its debt-to-equity ratio stands near 0.86x and the stock trades at 2.58x book value.
- Strong 3-year compounded profit growth of 39% indicates improving profitability and operating leverage across business segments
- TTM revenue growth of 12% and 3-year compounded sales CAGR of 17% demonstrate consistent top-line momentum
- Stock has delivered 54% CAGR over 3 years and 37% CAGR over 10 years, reflecting sustained long-term wealth creation
- FY26 net profit surged 56.5% YoY to ₹282 Cr from ₹180 Cr in FY25, showing an acceleration in earnings trajectory
- India's only integrated green petrochemical company using renewable agricultural feedstock, positioning it well for ESG-driven demand and ethanol-blending policies
- Diversified revenue streams across Bio-Based Chemicals, Potable Spirits, and Biopharma segments reduce single-segment dependency
- Dividend payout increased from 80% to 100% of face value in FY25, with total dividend outgo rising to ₹30.96 Cr from ₹24.77 Cr, signaling management confidence
- 10-year compounded profit CAGR of 74% reflects a long runway of earnings expansion from a low base
- Return on equity has averaged only 10% over 3, 5, and 10 years, indicating modest capital efficiency relative to the 25.9x P/E multiple
- Stock trades at 2.58x book value, which is elevated for a company generating just 10-11% ROE, suggesting limited margin of safety
- Debt-to-equity ratio near 0.86x implies meaningful financial leverage, increasing vulnerability to interest rate hikes or earnings slowdowns
- Dividend yield of only 0.66% offers limited income support at current valuations
- 5-year compounded profit growth of just 14% is significantly lower than the 3-year figure of 39%, indicating earnings volatility across cycles
- 10-year compounded sales CAGR of only 6% suggests historically sluggish top-line growth before the recent acceleration
- Commodity-linked business exposed to ethylene oxide and molasses price fluctuations, which can compress margins in adverse cycles
- Q3FY25 revenue of ₹975 Cr came below analyst estimates, highlighting execution risk and demand uncertainty in certain quarters
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- NCLT approves demerger scheme Jul 17
NCLT Allahabad Bench sanctioned the demerger of India Glycols' Bio Pharma and Spirits undertakings on July 17, 2026, enabling the company to unlock value through separate focused entities.
- Director appointed at subsidiary Aug 1
Akshay Bansal appointed as Additional Director and KMP at subsidiary Ennature Bio Pharma effective July 31, 2026, for a five-year term, addressing regulatory observations on the Scheme of Arrangement.
- 42nd AGM scheduled Aug 19 Jul 22
India Glycols will hold its 42nd AGM on August 19, 2026, via video conferencing to cover FY 2025-26 results.
TL;DR: India Glycols is progressing well on its corporate restructuring front with NCLT approval for the demerger of Bio Pharma and Spirits businesses, a move that should unlock standalone value. No visible headwinds in recent news flow. The management reshuffle at Ennature Bio Pharma signals preparation for post-demerger operations. The trend is constructive as the company moves toward a leaner, more focused structure.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 689 | 775 | 904 | 926 | 969 | 961 | 975 | 863 | 1,040 | 1,092 | 1,102 | 976 | 1,130 |
| Expenses | 589 | 679 | 802 | 822 | 843 | 845 | 852 | 717 | 891 | 935 | 927 | 810 | 961 |
| Operating Profit | 100 | 96 | 102 | 105 | 126 | 116 | 124 | 146 | 150 | 158 | 175 | 166 | 170 |
| OPM % | 15% | 12% | 11% | 11% | 13% | 12% | 13% | 17% | 14% | 14% | 16% | 17% | 15% |
| Other Income | 12 | 12 | 9 | 10 | 14 | 15 | 19 | 13 | 20 | 14 | 3 | 14 | 21 |
| Interest | 28 | 29 | 31 | 33 | 36 | 40 | 44 | 45 | 45 | 49 | 47 | 26 | 25 |
| Depreciation | 21 | 28 | 26 | 26 | 28 | 28 | 27 | 33 | 34 | 38 | 41 | 41 | 42 |
| PBT | 64 | 50 | 54 | 56 | 76 | 63 | 71 | 82 | 91 | 84 | 91 | 112 | 123 |
| Tax % | 20% | 24% | 23% | 24% | 20% | 22% | 20% | 22% | 19% | 22% | 25% | 23% | 21% |
| Net Profit | 51 | 38 | 42 | 42 | 60 | 50 | 57 | 64 | 73 | 65 | 68 | 87 | 97 |
| EPS in Rs | 8.26 | 6.14 | 6.73 | 6.82 | 9.75 | 8.03 | 9.18 | 10.34 | 11.83 | 10.51 | 10.08 | 12.96 | 14.45 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,579 | 2,324 | 2,500 | 3,034 | 3,357 | 2,735 | 2,317 | 2,868 | 2,651 | 3,294 | 3,768 | 4,211 | 4,301 |
| Expenses | 2,455 | 2,149 | 2,263 | 2,712 | 2,941 | 2,433 | 2,026 | 2,599 | 2,346 | 2,879 | 3,257 | 3,562 | 3,632 |
| Operating Profit | 124 | 175 | 237 | 322 | 416 | 303 | 291 | 269 | 305 | 415 | 511 | 649 | 669 |
| OPM % | 4.8% | 8% | 9% | 11% | 12% | 11% | 13% | 9% | 12% | 13% | 14% | 15% | 16% |
| Other Income | -16 | -47 | 7 | 23 | 17 | 24 | 15 | 260 | 54 | 30 | 61 | 50 | 51 |
| Interest | 163 | 139 | 127 | 125 | 143 | 97 | 83 | 70 | 100 | 121 | 164 | 167 | 148 |
| Depreciation | 89 | 69 | 72 | 73 | 76 | 78 | 80 | 80 | 94 | 101 | 115 | 155 | 163 |
| PBT | -144 | -81 | 45 | 147 | 213 | 153 | 143 | 379 | 165 | 223 | 292 | 377 | 410 |
| Tax % | -38% | -30% | 22% | 34% | 38% | 25% | 8% | 10% | 15% | 23% | 21% | 22% | — |
| Net Profit | -89 | -57 | 35 | 97 | 133 | 115 | 132 | 340 | 141 | 173 | 231 | 293 | 316 |
| EPS in Rs | -14.32 | -9.18 | 5.66 | 15.59 | 21.42 | 18.52 | 21.26 | 54.9 | 20.21 | 27.95 | 37.31 | 43.68 | 48 |
| Div. Payout % | 0% | 0% | 9% | 13% | 14% | 16% | 14% | 7% | 19% | 14% | 13% | 17% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 34 |
| Reserves | 266 | 687 | 721 | 814 | 932 | 1,003 | 1,138 | 1,761 | 1,870 | 2,020 | 2,225 | 2,899 |
| Borrowings | 2,264 | 1,236 | 1,095 | 834 | 1,000 | 999 | 1,137 | 1,047 | 1,112 | 1,348 | 1,892 | 1,691 |
| Other Liabilities | 593 | 1,665 | 1,645 | 1,742 | 1,821 | 2,053 | 1,814 | 1,792 | 1,845 | 2,218 | 2,029 | 1,900 |
| Total Liabilities | 3,154 | 3,620 | 3,492 | 3,421 | 3,784 | 4,086 | 4,119 | 4,631 | 4,858 | 5,617 | 6,176 | 6,523 |
| Fixed Assets | 1,146 | 2,029 | 2,111 | 2,156 | 2,173 | 2,228 | 2,193 | 2,318 | 2,717 | 3,205 | 3,829 | 4,554 |
| CWIP | 162 | 181 | 91 | 89 | 137 | 172 | 126 | 243 | 125 | 84 | 98 | 37 |
| Investments | 4 | 28 | 25 | 24 | 21 | 26 | 27 | 336 | 318 | 335 | 381 | 389 |
| Other Assets | 1,843 | 1,382 | 1,265 | 1,152 | 1,453 | 1,660 | 1,774 | 1,734 | 1,698 | 1,993 | 1,867 | 1,543 |
| Total Assets | 3,154 | 3,620 | 3,492 | 3,421 | 3,784 | 4,086 | 4,119 | 4,631 | 4,858 | 5,617 | 6,176 | 6,523 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -171 | 1,231 | 302 | 502 | 147 | 343 | 137 | 116 | 326 | 439 | 362 | 769 |
| Investing | 175 | -78 | -40 | -103 | -128 | -151 | -148 | 76 | -330 | -503 | -736 | -767 |
| Financing | -4 | -1,168 | -263 | -399 | 3 | -216 | 11 | -189 | -1 | 90 | 354 | 23 |
| Net Cash Flow | 0 | -15 | -1 | 0 | 22 | -23 | 0 | 4 | -5 | 25 | -20 | 25 |
| Free Cash Flow | -53 | 1,137 | 260 | 373 | 9 | 193 | -11 | -264 | -109 | -103 | -391 | -47 |
| CFO/OP | -136 | 705 | 127 | 156 | 37 | 127 | 53 | 51 | 123 | 108 | 75 | 122 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 62 | 57 | 57 | 40 | 35 | 76 | 57 | 51 | 59 | 43 | 35 | 30 |
| Inventory Days | 109 | 128 | 129 | 87 | 124 | 146 | 166 | 148 | 209 | 224 | 209 | 139 |
| Days Payable | 55 | 120 | 144 | 152 | 143 | 155 | 158 | 137 | 209 | 222 | 175 | 123 |
| Cash Conversion Cycle | 115 | 66 | 42 | -25 | 17 | 67 | 65 | 62 | 60 | 44 | 70 | 47 |
| Working Capital Days | -110 | -94 | -117 | -78 | -50 | -64 | -79 | -31 | -46 | -63 | -56 | -49 |
| ROCE % | 3% | 5% | 9% | 15% | 20% | 14% | 10% | 9% | 8% | 11% | 12% | 12% |
Documents
Frequently Asked Questions about India Glycols Ltd
What does India Glycols Ltd do?
Where is India Glycols Ltd (INDIAGLYCO) listed?
Which sector does India Glycols Ltd belong to?
What is the market capitalisation of India Glycols Ltd?
What is the PE ratio of India Glycols Ltd?
What is the 52-week high and low of India Glycols Ltd?
Does India Glycols Ltd pay dividends?
What is the Return on Equity (ROE) of India Glycols Ltd?
How can I research India Glycols Ltd on Tapetide?
Company Information
Established in 1988, India Glycols Ltd. is engaged in the manufacturing of green technology-based bulk, specialty & performance chemicals, and natural gums, spirits, industrial gases, sugar, and nutraceuticals. [1][2]